Study Limitations and Data Access
Cross-source consensus on Study Limitations and Data Access from 1 sources and 5 claims.
1 sources · 5 claims
Evidence quality
Where it comes from
Highlighted claims
- The study's limitations included being conducted only in the United States, having a predominantly white population, lacking a comparator arm continuing injectable therapy, and lasting one year. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Eli Lilly funded the study and was involved in design, data collection, analysis, interpretation, and writing. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Deaths, pancreatic adverse events, and cardiovascular events were adjudicated by a blinded independent external committee. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Rescue therapy protected participants but prevented a pure placebo comparison after week 24. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
- Lilly states it will provide anonymized individual participant data after specified regulatory and publication milestones, subject to review approval and a data-sharing agreement. — Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial